

Tabibiazar Raymond  
Form 4  
October 16, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
*See Instruction*  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Tabibiazar Raymond

(Last) (First) (Middle)

C/O ARVIVE,  
INC., LYONDELLBASEL TOWER,  
1221 MCKINNEY ST.

(Street)

HOUSTON, TX 77010

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol  
Aravive, Inc. [ARAV]

3. Date of Earliest Transaction  
(Month/Day/Year)  
10/12/2018

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☐ Director ☒ 10% Owner  
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/12/2018		A		1,000,751	A	<u>11</u> 1,000,751

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form  
displays a currently valid OMB control  
number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Tabibiazar Raymond - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 0.06	10/12/2018		A		46,322		<u>(2)</u>	04/25/2021	Common Stock	46,322
Stock Option (Right to Buy)	\$ 0.06	10/12/2018		A		12,084		<u>(3)</u>	04/25/2021	Common Stock	12,084
Stock Option (Right to Buy)	\$ 0.24	10/12/2018		A		51,682		<u>(4)</u>	09/30/2024	Common Stock	51,682
Stock Option (Right to Buy)	\$ 0.24	10/12/2018		A		15,200		<u>(5)</u>	12/31/2024	Common Stock	15,200
Stock Option (Right to Buy)	\$ 0.24	10/12/2018		A		15,200		<u>(6)</u>	03/31/2025	Common Stock	15,200
Stock Option (Right to Buy)	\$ 0.24	10/12/2018		A		15,200		<u>(7)</u>	06/30/2025	Common Stock	15,200
Stock Option (Right to Buy)	\$ 0.24	10/12/2018		A		65,365		<u>(8)</u>	06/30/2025	Common Stock	65,365
Stock Option (Right to Buy)	\$ 0.24	10/12/2018		A		254,177		<u>(9)</u>	06/30/2025	Common Stock	254,177
Stock Option (Right to Buy)	\$ 0.24	10/12/2018		A		15,200		<u>(10)</u>	09/30/2025	Common Stock	15,200
	\$ 0.24	10/12/2018		A		15,200		<u>(11)</u>	12/31/2025		15,200

Stock Option (Right to Buy)								Common Stock	
Stock Option (Right to Buy)	\$ 0.24	10/12/2018	A	15,200	<u>(12)</u>	03/31/2026	Common Stock	15,200	
Stock Option (Right to Buy)	\$ 0.66	10/12/2018	A	57,002	<u>(13)</u>	06/15/2027	Common Stock	57,002	
Stock Option (Right to Buy)	\$ 0.9	10/12/2018	A	28,501	<u>(14)</u>	12/14/2027	Common Stock	28,501	
Stock Option (Right to Buy)	\$ 0.9	10/12/2018	A	28,501	<u>(15)</u>	03/20/2028	Common Stock	28,501	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Tabibiazar Raymond C/O ARAVIVE, INC. LYONDELLBASEL TOWER, 1221 MCKINNEY ST. HOUSTON, TX 77010	X	X		

## Signatures

/s/ Kevin Haas,  
Attorney-in-fact

10/16/2018

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Shares of common stock of the corporation known as Aravive Biologics, Inc. ("Aravive") were converted into shares of the issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 3, 2018, by and among the Issuer, Velo Merger Sub, Inc. and Aravive (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of Aravive common stock was exchanged for 2.2801 shares of the Issuer's common stock, subject to adjustment for any reverse stock split. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every six shares of Issuer common stock outstanding and the Issuer changed its name to Aravive, Inc. All share and option numbers reflect the reverse stock split.
- (2) On April 26, 2011, Reporting Person was granted an option to purchase 121,897 shares of the common stock of Aravive at an exercise price of \$0.02 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 46,332 shares of Issuer



## Edgar Filing: Tabibiazar Raymond - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.